Therapeutic Area: Cancer

Phase 2 Monotherapy Study in Glioblastoma Multiforme

 Status: Ongoing, Enrollment Complete

This is an open-label, multiple-dose study in subjects with glioblastoma multiforme. The primary endpoint for this study is 6-month Progression Free Survival (PFS) compared against historical control. The secondary endpoints include overall response observed over a maximum of 18 months of follow-up and overall survival. This study is being conducted at 10 sites in the US.

Visit clinicaltrials.gov for more information:
http://www.clinicaltrials.gov/ct2/show/NCT00892931

Phase 2 Combination Study in Glioblastoma Multiforme

Status: Ongoing, Enrollment Complete

This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with carboplatin.

Visit clinicaltrials.gov for more information:
http://clinicaltrials.gov/ct2/show/NCT00635557

Phase 2 Combination Study in Metastatic Melanoma

Status: Complete 

Myrexis has completed an open-label, dose finding, multiple-dose study in subjects with metastatic melanoma. Three dose levels of MPC-6827 were administered with temozolomide to three separate cohorts. Study endpoints include determination of the maximum tolerated dose, determination of dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with temozolomide.

Visit clinicaltrials.gov for more information:
http://clinicaltrials.gov/ct2/show/NCT00609011

Phase 1 Clinical Trial (Metastatic Solid Tumors, with or without brain metastases)

Status: Completed

Myrexis has completed a Phase 1 clinical trial for Azixa™ (MPC-6827) at the M.D. Anderson Cancer Center in Houston and the Huntsman Cancer Center in Salt Lake City. The study was designed to evaluate the safety and pharmacokinetic profile of MPC-6827 in patients with advanced solid tumors, in an escalating dose regimen.

Visit clinicaltrials.gov for more information:
http://www.clinicaltrials.gov/ct/show/NCT00394446

Phase 1 Clinical Trial (Metastatic Brain Cancer)

Status: Completed

Myrexis has completed an open label, dose escalating, multiple dose study to determine the safety, tolerability, maximum tolerated dose, and pharmacokinetics of MPC-6827 in subjects with refractory brain metastases. This study was performed at the M.D. Anderson Cancer Center in Houston.

Visit clinicaltrials.gov for more information:
http://www.clinicaltrials.gov/ct/show/NCT00393965 

Contact Us: clinical.trials@myrexis.com